Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company that operates a growing contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, has announced a definitive development and clinical manufacturing agreement through its wholly owned subsidiary, Scinai Biopharma Services Ltd. The agreement, signed with a U.S.-based, Nasdaq-listed biopharmaceutical company, includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. This deal expands an existing customer relationship and covers development and clinical manufacturing services for an investigational oncology product.
Revenue from the agreement is expected during 2026 and 2027, with stability services extending beyond 2027. Following the signing, Scinai's committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million. That figure represents a 300% increase from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026. The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones.
The significance of this announcement lies in its demonstration of Scinai's ability to convert its CDMO capabilities into substantial, recurring revenue streams. The $5.1 million commitment not only validates the company's manufacturing expertise but also provides a near-term revenue backlog that supports financial stability. More importantly, the 300% surge in committed orders since the end of 2025 signals accelerating demand for Scinai's services, which could lead to improved margins and greater operational leverage as fixed costs are spread over a larger revenue base.
For investors, the agreement reduces reliance on the company's therapeutic development pipeline, which is inherently risky and capital-intensive. By building a robust CDMO business, Scinai creates a more diversified revenue profile, with cash flows from services potentially funding its immunology research. The Jerusalem and Yavne facilities are now positioned to benefit from economies of scale, which may enhance profitability as order volume grows. Furthermore, the potential additional $5.85 million in uncommitted work suggests a pipeline of future opportunities that could sustain growth beyond 2027.
Scinai Immunotherapeutics continues to advance a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI. For a deeper look at the company's CDMO services and strategic relationships, see Scinai Immunotherapeutics (NASDAQ: SCNI).
The full press release can be viewed at https://ibn.fm/5jaNp. MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. For more information, visit MissionIR.
